In December 2018, of the total 16 analysts covering Endo International (ENDP), five analysts have given Endo stock a “buy” or higher rating and 11 analysts have given it a “hold” rating. The mean rating for Endo International stock is 2.5 with a target price of $17.04, implying an upside potential of 47.3% over Endo International’s closing price of $11.57 on December 7, 2018.
In comparison, for peers Abbott Laboratories (ABT), Johnson & Johnson (JNJ), and Pfizer (PFE), analysts have a mean rating of 1.76, 2.32, and 2.72, respectively, and a target price of $79.44, $148.11, and $44.15, respectively.
Its current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 1.10. In comparison, the current ratios of Abbott Laboratories (ABT), Johnson & Johnson (JNJ), and Pfizer (PFE) stand at 1.40, 1.70, and 1.40, respectively.
After a strong run from $5.43 on May 3, 2018, to a high of $18.39 on October 16, 2018, Endo stock has witnessed selling pressure and corrected to $13.89 on November 8, 2018. Subsequently, Endo International stock has continued its downward slide to its present $11.6 levels in December 2018.
The enterprise value of Endo International is $9.74 billion, and its enterprise value to revenue ratio is 3.33x. The stock is trading at a forward PE multiple of 4.24x. Its price-to-sales ratio is 0.89x. In comparison, the price-to-sales ratios of Abbott Laboratories (ABT), Johnson & Johnson (JNJ), and Pfizer (PFE) stand at 4.13x, 4.81x, and 4.89x, respectively.